

Pharmacophore

(An International Research Journal)

Available online at <http://www.pharmacophorejournal.com/>

Review Article

HDAC INHIBITORS: A NEW ARMOUR IN ANTI-CANCER THERAPEUTICS

Rajkumar Saharan^{1*}, Rambir Singh¹, Narendra Nagar¹, Sanjay Verma¹,
Vineet Sharma¹, Sanjay Yadav², Nagori B.P.³

^{1*} Department of Medicinal Chemistry and Drug Discovery,
Suresh Gyan Vihar University,
Jaipur, Rajasthan, India

² Department of Pharmacology, NIMS University,
Jaipur, Rajasthan, India

³ L.M.College of Science and Technology (Pharmacy),
Shastri Nagar, Jodhpur, Rajasthan, India

ABSTRACT

Histone deacetylase inhibitors (HDACi) are one of the new anti-cancer agents and in fact vorinostat has been approved by the FDA for the treatment of cutaneous T-cell lymphoma. Several classes of HDACi have been identified including organic hydroxamic acids like TSA and SAHA, Short-chain fatty acids like butyrates and valproic acid, benzamides like MS-275, cyclic tetrapeptides like trapoxin and sulfonamide anilides and others. Histone deacetylase inhibitors (HDACi) de-repress genes that results in growth inhibition, differentiation and apoptosis of cancer cells. Vorinostat (SAHA), romidepsin (depsipeptide, FK-228), belinostat (PXD101) and LAQ824 have confirmed therapeutic benefits in cutaneous T-cell lymphoma (CTCL) without combination therapy and have also demonstrated some therapeutic benefit in other malignancies. Beyond cancer, there may be several novel therapeutic areas where HDACi may provide therapeutic benefits like in *Inflammation*, *Polycythemia vera*, essential *Thrombocythemia*, *Myelofibrosis* and *Neurodegenerative* diseases such as *Alzheimer's* disease and *Huntington's* disease. Belinostat appears to be promising for treating low malignant potential ovarian tumor. The combination of azacitidine, valproic acid, and all trans-retinoic acid has significant clinical activity in leukemia. Epigenetic agents in combination regimens for cancer therapy are being actively studied.

Keywords: HDACi, SAHA, Hydromates, Cutaneous T-cell Lymphoma, Apoptosis.

INTRODUCTION

Enzyme plays a vital role in living organism, in mediating and regulating various biochemical processes including metabolism, catabolism,

cellular transduction, cell cycling and development. However, various disorders in human are caused by the dysfunction of enzyme as well as their hyper expression. Histone

deacetylase (HDACs) is an important class of enzyme which plays an important role in transcriptional regulation.¹ The HDAC family is divided into the Zn-dependent (Class I and Class II) and NAD-dependent (Class III) enzymes. The Zn-dependent enzymes have been the focus of intense research, while the Sir2 family recently implicated in acetylation and regulation of key cell cycle proteins such as p53.² Till date, eleven HDAC family members in Classes I and II have been characterized i.e. HDACs 1, 2, 3, 8 are Class I and HDACs 4, to 7, 9 and 10 are Class II, a grouping based on sequence similarity (Table1).³ The most recently identified member of HDAC family is HDAC 11, most likely Class

I, although its similarity to HDAC 1 is weak. Inhibitors of these enzymes are known to induce cell cycle arrest, p53 independent induction of cyclin dependent kinase inhibitor p21, tumor selective apoptosis, and differentiation of normal and malignant cells. So, this direct and indirect effect of HDAC enzyme on tumour cells and metastasis makes histone deacetylase inhibitors (HDACi) as a potential class of anti-cancer agent. SAHA is the first HDACi to meet the FDA Approval for the treatment of cutaneous T cell lymphoma. Several other small molecules which inhibit the HDAC are under clinical trial for cancer.⁴

Table 1: Classification of HDAC family

Zn -Dependant HDAC		NAD- Dependant HDAC
Inhibited by TSA		Inhibited by Nicotinamide
Class I	Class II	Class III
HDAC 1	HDAC 4-7	SIRT 1-7
HDAC 2	HDAC 9	
HDAC 3	HDAC 10	
HDAC 8		
HDAC 11		




Figure1: Some important HDAC inhibitors

Classification


The Classical HDACi acts entirely on class I and class II HDACs by binding to the zinc-containing catalytic domain of the HDACs. Several classes of HDACi have been identified, including (a) organic hydroxamic acids

e.g. Trichostatin A (TSA) and suberoyl anilide hydroxamic acid (SAHA), (b) short-chain fatty acids e.g., butyrates and valproic acid (VPA), (c) benzamides e.g. MS-275, (d) cyclic tetrapeptides e.g., trapoxin and (e) sulfonamide anilides and others (Table 2).


Table 2: Classification of HDACi based on Chemical Structure

Class	Compound	Chemical Structure
Hydroxamates	TSA (Trichostatin)	
	SAHA (Vorinostat)	
CBHA		


LAQ-824(Dacinostat)




PDX-101(Belinostat)



LBH-589(Panobinostat)




ITF-2357(Givinostat)




Cyclic peptide


Depsipeptide(Romidepsin)




Apicidin




Trapoxins





Others

Depudecin



Mechanism of Action of HDAC Inhibitors

HDAC enzymes remove the acetyl group from histones using a charge-relay mechanism consisting of two adjacent histidine residues, two aspartate residues and one tyrosine residue, and crucial for this charge-relay system is a Zn^{2+} ion, which binds deep in the pocket of the enzyme.⁶ There are a large number of literatures which indicates that HDAC Inhibitors blocks the cell cycle and induce differentiation depending on the cell type and environmental factors.⁷ HDAC Inhibitors such as trichostatin A (TSA), SAHA and PXD101, acts by displacing the zinc atom. There are two major pathways of apoptosis, first „„extrinsic” or death-receptor pathway and second the „„intrinsic” or mitochondrial pathway.

All HDAC inhibitors have been reported to follow either one or both of these cell death pathways in many cancer models. The proposed mechanisms of cancer cell death resulting from HDAC inhibitor treatment are as following.

- I. Death receptor (extrinsic) pathway of apoptosis
- II. Mitochondrial (intrinsic) pathway of apoptosis
- III. Inhibition of angiogenesis
- IV. Generation of reactive oxygen species (ROS)
- V. Autophagy etc.




Figure2: Mechanisms of HDAC inhibitor-induced cell death

HDAC inhibitors have a multiple effects on cancer cells. HDAC inhibitors also induce apoptosis via both the extrinsic and intrinsic pathway. Apoptosis stimulated by HDAC inhibitors is associated with increased expression of pro-apoptotic genes and decreased expression of anti-apoptotic genes, thus shifting the balance

toward cell death. Due to this effect, HDAC inhibitors enhance the efficacy of many pro-apoptotic conventional anticancer agents. Another significant effect associated with HDAC inhibitor-mediated cell death is the generation of reactive oxygen species, ROS. ROS play an important role in activating the intrinsic pathway

of apoptosis. In addition to promoting apoptotic cell death, HDAC inhibitors have also been reported to inhibit tumor angiogenesis and induce autophagy, which may also contribute to their mechanism of action. However, recent evidence suggests that the stimulation of autophagy by HDAC inhibitors may promote survival and thus reduce therapeutic efficacy

since its inhibition greatly potentiates HDAC inhibitor-induced cell death.

Chemistry of Novel HDAC Inhibitors

The classic pharmacophore of HDAC inhibitors consists of three distinct structural parts (a) the zinc-binding group (b) hydrophobic Linker and (c) recognition cap group.




Figure3: FDA approved HDAC inhibitor, SAHA

HDACi can be divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids, and benzamides.⁹ TSA was the first natural hydroxamate discovered to inhibit HDACs.¹⁰ Vorinostat is structurally similar to TSA. A series of aminosuberoyl hydroxamic acids have recently been discovered to inhibit HDACs and transform cell proliferation at nanomolar concentrations. Vorinostat is the first HDACi to be approved for clinical use by the Food and Drug Administration.¹¹ Vorinostat is a pan-inhibitor of class I and class II HDAC proteins. M-Carboxycinnamic acid bishydroxamate is a potent HDACi¹² and is the structural basis for several derivatives including LAQ-824, LBH-589 and a sulfonamide derivative, PXD-101 (Belinostat). These HDACi inhibit class I and class II HDACs. Panobinostat (LBH-589) is a cinnamic hydroxamic acid analogue of M-carboxycinnamic acid bishydroxamate. IF2357 (Italfarmaco) is an HDACi that contains a hydroxamic acid moiety linked to an aromatic ring. The cyclic peptide class is a structurally complex group of HDACi, which includes the natural product depsipeptide (Romidepsin, FK-228), apicidine and the cyclic

hydroxamic acid containing peptide group of molecules, all are active at nanomolar concentrations.¹³ The aliphatic acids like butyrate, phenylbutyrate and valproic acid are relatively weak inhibitors of the HDACs, with activity at millimolar concentration.¹⁴ Both valproic acid and phenylbutyrate are drugs that are in the market for non-oncological uses like in neurology and psychiatry and were recently shown to have activity as HDACi. MGCD0103 is dihydrobromide salt of a substituted 2-aminophenyl benzamide.¹⁵ Two novel synthetic compounds, SK7041 and SK7068 preferentially target HDAC1 and HDAC2. A small molecule, tubacin, selectively inhibits HDAC6 activity and causes accumulation of acetylated tubulin, but does not affect acetylation of histones and does not inhibit cell cycle progression.¹⁶ It remains to be determined whether selective inhibition of HDACs would be advantageous over pan-inhibition of HDACs in cancer treatment.¹⁷ In prototypical HDAC inhibitor, the capping group is solvent-exposed and interacts with amino acids near the entrance of the active site. The metal binding group resides in the protein interior and complexes the metal ion involved in

catalysis. The linker serves to position the capping and metal binding groups approximately for high-affinity interactions with proteins. The incorporation of substituent on the linker adjacent to the metal binding moiety has a variable influence on inhibitory activity.

Other Disease That May Be Treated With HDACi

Beyond cancer there may be several novel therapeutic areas where HDACi may provide therapeutic benefits. Early in the investigations on HDAC inhibitors it was recognized that one of the effects was the activation of latent viruses (e.g., HIV). As this may be problematic in the development of HDACi, this mechanism can be utilized to reactivate a latent virus thus making it susceptible to subsequent treatment with targeted anti-viral therapy.¹⁸ This concept has been validated in humans with valproic acid, the HDACi and highly active antiretroviral therapy where resting cell infection declined significantly in three out of four patients treated with this combination.¹⁹ HDACi can reduce graft-versus-host disease following bone marrow transplantation by suppressing pro-inflammatory cytokines such as TNF α .²⁰ Also, HDACi have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptics. For example valproic acid, marketed as a drug under the trade names Depakene, Depakote, and Divalproex. In more current times, HDACi are being studied as a drug for neurodegenerative diseases such as Alzheimer's disease and Huntington's disease.²¹ Enhancement of memory formation is increased in mice with HDACi like sodium butyrate or SAHA, is also observed.²² Trichostatin A (TSA) and others are being investigated as anti-inflammatory agents.²³ ITF2357 (Givinostat) is under investigation for treatment of polycythemia vera (PV), Essential thrombocythemia (ET) and Myelofibrosis (MF).²⁴ AR-42 has started clinical trials in 2010 for various cancers like relapsed or treatment-

resistant multiple myeloma, chronic lymphocytic leukemia or lymphoma.²⁵

FDA Approved and Under Clinical Trial HDACi

Vorinostat (SAHA, Zolinza®), a hydroxamate-based inhibitor was the first HDACi to be approved by the Food and Drug Administration (FDA) in 2006 for the treatment of CTCL for patients who had already received two or more prior systemic therapies. It has long been considered to inhibit all zinc-dependent HDACs in the nanomolar conc. Recent studies suggest that it has only weak inhibitory effect on class IIa enzymes.²⁶ Romidepsin (Istodax®), a structurally different cyclic peptide (depsipeptide or FK-228), was second HDAC inhibitor that approved by the FDA at the end of 2009. Romidepsin was isolated from *Chromobacterium violaceum* and inhibits the activity of HDACs at nanomolar conc. This compound inhibits if at all possible class I HDACs and is therefore called a class-selective inhibitor in compare to Vorinostat which also acts robustly on HDAC6. Besides its approval for CTCL, Romidepsin is investigated as a treatment option in other cancer types as monotherapy as well as in combination therapy.²⁷ Panobinostat (LBH589) is in clinical trials for various cancers including a phase III trial for cutaneous T cell lymphoma (CTCL).²⁸ Valproic acid, as Mg valproate is in phase III trials for cervical cancer and ovarian cancer. Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trial in phase II for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myeloid leukemia. Givinostat (ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and anti-neoplastic activities.²⁹ Belinostat is in phase II trial with NDA submission planned for 2011. Entinostat (MS-275) is in phase II for Hodgkin lymphoma, lung cancer and breast cancer.³⁰

CONCLUSION

In this review we summarize studies on classification, mechanism of action, chemistry and the use of HDACi. Many questions are currently still unveiled with respect to HDACi mechanism of action, specificities for definite tumor and the regulation mechanisms of the specific gene expression. Also, it is important to distinguish the HDAC specificity of HDACi for the development of selective therapy on the molecular level. Epigenetic agents in combination regimens for cancer therapy are

REFERENCES

1. Bayle, JH and Crabtree, GR (1997), "Protein acetylation: more than chromatin modification to regulate transcription", *Chem Biol*, Vol.4, 885-888.
2. Cheng, HL; Gu, Y; Mostoslavsky, R; Saito, S *et al.* (2003), "Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice", *Proc Natl Acad Sci*, Vol.100, 10794-10799.
3. Ruijter, AJM; Van Gennip, AH; Caron, HN; Kemp, S *et al.* (2003), "Histone deacetylases (HDACs): characterization of the classical HDAC family", *Biochem J*, Vol. 370,737-749.
4. Anton, VB; Sujith, VW and Mary Kay HP (2007), "Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid", *Bioorganic Chemistry and Organic letters*, Vol.17, 2216-2219.
5. Takai, N and Narahara H (2007), "Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis", *Current Medicinal Chemistry*, Vol. 14, 2548-2553.
6. Finnin, MS; Donigian, JR; Cohen, A; Richon, VM *et al.* (1999), "Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors", *Nature*, Vol.401, 188-93.
7. Prakash, S; Foster, BJ; Meyer, M; Wozniak, A *et al.*(2001) "Chronic oral administration of CI-994", *Invest New Drugs*, Vol.19, 1-11.
8. Rosato, RR; Almenara,JA; Dai,Y; Grant,S *et al.*(2003), " Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells", *Mol. Cancer Ther.*, Vol.2, 1273-1284.
9. Miller, TA; Witter, DJ; Belvedere, S *et al* (2003), "Histone deacetylase inhibitors", *J MedChem*, Vol.46, 5097 - 5116.
10. Yoshida, M; Kijima, M; Akita, M; Beppu, T (1990), "Potent and specific inhibition of Mammalian histone deacetylase both in vivo and in vitro by trichostatin A", *J Biol Chem*, Vol. 265, 17174 - 17179.
11. Duvic, M; Talpur, R; Ni, X *et al.* (2007), "Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)", *Blood*, Vol.109, 31 -39.
12. Richon, VM; Emiliani, S; Verdin, E (1998), "A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases", *Proc Natl Acad Sci*, Vol.95, 3003 -3007.

13. Jose, B; Oniki, Y; Kato, T; Nishino, N *et al.* (2004), "Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones", *Bioorg Med Chem Lett*, Vol.14, 5343 – 5346.
14. Rasheed, WK; Johnstone, RW; Prince, HM (2007), "Histone deacetylase inhibitors in cancer therapy", *Expert Opin Investig Drugs*, Vol.16, 659 – 678.
15. Miller, TA; Witter, DJ; Belvedere, S (2003), "Histone deacetylase inhibitors", *J Med Chem*, Vol.46, 5097 – 5116.
16. Haggarty, SJ; Koeller, KM; Wong, JC; Grozinger CM *et al.* (2003), "Domain selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation", *Proc Natl Acad Sci*, Vol.100, 4389 – 4394.
17. Karagiannis, TC; Osta, A (2007), "Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds", *Leukemia*, Vol.21, 61 –65.
18. Lehrman, G; Hogue, IB; Palmer, S; Jennings C *et al.* (2005), "Depletion of latent HIV-1 infection in vivo: a proof-of-concept study", *Lancet*, Vol.366 (9485), 549–555.
19. Ylisastigui, L; Archin, NM; Lehrman, G; Bosch, RJ *et al.* (2004), "Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression", *AIDS*, Vol. 18(8), 1101–1108.
20. Bolden, J; Peart, M; Johnstone, R (2006), "Anticancer activities of histone deacetylase inhibitors", *Nat Rev Drug Discov*, Vol.5, 769–784.
21. Hahnen, E; Hauke, J; Trankle, C; Eyupoglu, IY *et al.* (2008), "Histone deacetylase inhibitors: possible implications for neurodegenerative disorders", *Expert Opin Investig Drugs*, Vol.17 (2), 169–184..
22. Guan, JS; Haggarty, SJ; Giacometti, E; Dannenberg, JH *et al.* (2009), "HDAC2 negatively regulates memory formation and synaptic plasticity", *Nature*, Vol. 7(7243), 55–60.
23. Iwata, K. *et al.* (2002), "Trichostatin A, a histone deacetylase inhibitor, down-regulates interleukin-12 transcription in SV-40-transformed lung epithelial cells", *Cell Immunol*, Vol.218, 26–33.
24. Galli M *et al.* (2010), "A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma", *Ann Hematol* Vol.89,185–190
25. Marks, PA and Dokmanovic, M (2005), "Histone deacetylase inhibitors: discovery and development as anticancer agents", *Expert opinion on investigational drugs*, Vol.14 (12), 1497–1511.
26. Bradner, JE *et al.* (2010), "Chemical phylogenetics of histone deacetylases", *Nat Chem Biol*, Vol.6, 238–243.
27. Kim Y *et al.* (2008), "Clinically significant responses achieved with Romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2b, international, multicenter, registration study", *Blood*, Vol.112, 263.
28. Garbes, L; Riessland, M; Holker, I; Heller, R *et al.* (2009), "LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate", *Human Molecular Genetics*, Vol.18 (19), 3645–3658.
29. Leoni, F and Fossati, G (2005), "The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo", *Molecular Medicine*, Vol.11, 1.
30. Cang, S; Ma, Y; Petrillo, RL; Liu, D (2010), "Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents", *Journal of hematology & oncology*, Vol.3 (5), 8722-8725.